Patents by Inventor Dhananjai Srivastava

Dhananjai Srivastava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10227317
    Abstract: Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: March 12, 2019
    Assignee: LUPIN LIMITED
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Paramvir Bhadwal, Inamus Saqlain Ansari, Nilesh Shashikant Bhawsar
  • Publication number: 20180030008
    Abstract: Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.
    Type: Application
    Filed: February 24, 2016
    Publication date: February 1, 2018
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Paramvir Bhadwal, Inamus Saqlain Ansari, Nilesh Shashikant Bhawsar
  • Patent number: 9040688
    Abstract: The process of the present invention relates to a method for the synthesis of a 1,4-diphenylazetidinone of formula (VIII) by using novel oxime intermediates.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 26, 2015
    Assignee: LUPIN LIMITED
    Inventors: Dhananjai Srivastava, Rajiv Kumar Shakya, Namrata Anil Chaudhari, Inamus Saqlain Ansari, Girij Pal Singh
  • Publication number: 20130296562
    Abstract: The present invention relates to a stereoselective glycosylation for the preparation of 1,3-oxathiolane nucleoside in high yield and high optical purity. The invention specifically relates to a process of the preparation of Lamivudine and Emtricitabine using zirconium (IV) chloride (ZrCl4) as a catalyst in glycosylation.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 7, 2013
    Applicant: LUPIN LIMITED
    Inventors: Bhairab Nath Roy, Girij Pal Singh, Dhananjai Srivastava, Umesh Parasharam Aher, Sudhakar Uttam Patil
  • Patent number: 8158607
    Abstract: The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (?) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray diffractogram, as disclosed herein, is disclosed along with a process for preparation of the same. A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: April 17, 2012
    Assignee: Lupin Limited
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Manmeet Brijkishore Saini, Pritesh Rameshbhai Upadhyay
  • Publication number: 20120029185
    Abstract: The process of the present invention relates to a method for the synthesis of a 1,4-diphenylazetidinone of formula (VIII) by using novel oxime intermediates.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 2, 2012
    Inventors: Dhananjai Srivastava, Rajiv Kumar Shakya, Namrata Anil Chaudhari, Inamus Saqlain Ansari, Girij Pal Singh
  • Publication number: 20110288298
    Abstract: A polymorph of emtricitabine, wherein said polymorph displays angular positions of characteristic peaks in powder X-ray diffraction pattern 13.61±0.2, 15.54±0.2, 19.49±0.2, 20.55±0.2, 25.89±0.2, 28.09±0.2 and 29.10±0.2. A pharmaceutical composition comprising a polymorph of emtricitabine displaying angular positions of characteristic peaks in powder X-ray diffraction pattern 13.61±0.2, 15.54±0.2, 19.49±0.2, 20.55±0.2, 25.89±0.2, 28.09±0.2 and 29.10±0.2. A process for the preparation of a polymorph of emtricitabine comprising the steps of (a) dissolving crude emtricitabine in polar organic solvent by heating at a temperature of at least 40° C. and not more than 150° C. to form a reaction mixture optionally decreasing the concentration of polar organic solvent in said reaction mixture; cooling the reaction mixture obtained in step (a); and separating the solid from the cooled reaction mixture resulted in step (b).
    Type: Application
    Filed: November 12, 2008
    Publication date: November 24, 2011
    Applicant: LUPIN LIMITED
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Harishchandra Jadhav, Shailendra Pathak, Manmeet Saini, Sudhakar Patil
  • Publication number: 20110257396
    Abstract: An improved process for the manufacture of Lamivudine. The process involves: (a) resolution of racemic lamivudine (intermediate of formula IX) to cis (±) lamivudine of formula (XII) by forming a crystalline salt and separating the product from an organic solvent by fractional crystallization; (b) resolution of cis (±) lamivudine to cis (?) isomer involving formation of S-Binol adduct of formula XIV.
    Type: Application
    Filed: September 10, 2007
    Publication date: October 20, 2011
    Applicant: Lupin Limited
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Srinivas Ayyalasomayajula Satya, Manmeet Brijkishore Saini, Harishchandra Sambhaji Jadhav, Aparna Murlidharan Warrier, Nilesh Bhimsingh Dumre
  • Publication number: 20090281053
    Abstract: The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (?) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray diffractogram, as disclosed herein, is disclosed along with a process for preparation of the same. A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans.
    Type: Application
    Filed: February 9, 2007
    Publication date: November 12, 2009
    Applicant: LUPIN LIMITED
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Manmeet Brijkishore Saini, Pritesh Rameshbhai Upadhyay
  • Publication number: 20060149056
    Abstract: The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir and a process for the preparation thereof. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.
    Type: Application
    Filed: March 2, 2006
    Publication date: July 6, 2006
    Applicant: LUPIN LTD
    Inventors: Girij Singh, Himadri Sen, Dhananjai Srivastava, Himanshu Godbole, Gurvinder Singh, Pravin Mahajan, Umesh Rananaware, Sagar Nehate, Sanjay Wagh
  • Publication number: 20050245738
    Abstract: The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir and a process for the preparation thereof. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.
    Type: Application
    Filed: May 3, 2004
    Publication date: November 3, 2005
    Applicant: LUPIN LTD
    Inventors: Girij Singh, Himadri Sen, Dhananjai Srivastava, Himanshu Godbole, Gurvinder Singh, Pravin Mahajan, Umesh Rananaware, Sagar Nehate, Sanjay Wagh